November 13, 1998
Characteristics for Groups 1 and 2, respectively are as follows: CD4 count (332 vs. 409); CD4 nadir (151 vs. 350); CD4 increase (184 vs. N/A); on combination antiretroviral therapy (53% vs. 26%); and being on a protease inhibitor (24% vs. 6%). The risk for PCP was low for all groups evaluated; for Group 1 it was 0.8 cases of PCP/100 person-year at risk vs. 0.7 cases of PCP/100 person-year at risk for Group 2. These rates of PCP were calculated for the 3 cases of PCP over the 471 person-years of observation in Group 1 and 32 cases of PCP in the 4200 years of observation among individuals in Group 2. The CD4 nadir among the individuals in Group 1, particularly for those whose CD4 nadir was < 25 cells/µL. For this sub-group, there was one case of PCP in 23 person years of observation (4.4 cases/100 p-yrs), compared to 2 cases of PCP in 448 years of observation (0.5 cases/ 100 p-yrs) among individuals whose nadir CD4 ranged from 25 to 200 cells/µL. Though this did not achieve statistical significance, had the observation period been longer for the patients with the most advanced disease, significance may have been achieved, suggesting for this group of patients, continuing PCP prophylaxis may be warranted until further data are available.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.